Sanofi refocuses on specialty medicines in the U.S., amid pressure in diabetesLes Echos (p16) on Monday published an article on Sanofi’s efforts in specialty medicines on the U.S. market, as the company faces pressure on its main activity in the country, diabetes.
Aspen invests €25 million in French plantTuesday’s Les Echos (p25) reported that South African pharma Aspen is to invest €25 million in a new production line for its French site near Rouen in Normandy.
Therapeutic software company launches IPOLes Echos (p30) on Wednesday announced that French IT company Voluntis, which develops software to help patients suffering from chronic disease to manage their treatment, has decided to launch an IPO.
Takeda expects lower earnings after Shire acquisitionTuesday’s Les Echos (brief p18) noted that Takeda announced its operational result should decline to €1.6 billion for the 2019 fiscal year (ending March 2019), compared to €1.84 billion in 2018, due to the impact of the acquisition of Shire.
Novartis General Counsel steps down over controversial deal with Trump attorneyThursday’s Les Echos (brief p24) briefly reported on the resignation of Novartis General Counsel, Felix Ehrat, in the wake of the firm’s controversial $1.2 million contract with U.S. President Donald Trump’s attorney Michael Cohen (APMHE 58109).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.